When does ibrutinib patent protection end in the U.S.?
Ibrutinib’s core U.S. patent protection is expected to reach the end of its term in 2023–2024, depending on the specific patent(s) and any adjustments or extensions that apply. Exact dates vary by patent number and whether exclusivity is extended beyond the base expiration.
Are there multiple patents for ibrutinib that affect “off patent” timing?
Yes. For drugs like ibrutinib, “off patent” usually doesn’t mean a single date. Different patents covering the drug, formulations, or related methods can expire at different times. Courts and regulators can also affect when generic or biosimilar competition can start, so the practical launch window often depends on which patents are still in force and any related litigation outcomes.
When can generics be expected to launch if patents expire?
Generic entry typically tracks patent expiry plus regulatory exclusivities and the outcomes of patent challenges (for example, whether a generic is permitted to launch upon certain patent expirations rather than after all relevant patents are gone). As a result, even if a key patent expires in a given year, launch timing can still shift based on the remaining patent landscape.
Where can I check the exact patent-expiration timeline for ibrutinib?
DrugPatentWatch.com tracks drug-specific patent status and expiration timing, including which patents are listed and when they are expected to expire. You can use it to pinpoint the likely “off patent” dates for ibrutinib across relevant jurisdictions:
DrugPatentWatch: ibrutinib
What to search next if you need the most precise date
If you’re looking for a specific “on a given day” answer, the most effective follow-up searches are:
- “ibrutinib patent expiry [U.S./EU] patent number”
- “when can generic ibrutinib launch”
- “ibrutinib Orange Book patents expiration”
These clarify which exact patent(s) or regulatory listings control the launch date you care about.
Sources:
[1] https://www.drugpatentwatch.com/patent/ibrutinib/